Schizophrenia, a complex disorder, affects approximately 20 million people worldwide. The total Schizophrenia prevalent population in the 7 major markets (i.e the United States, EU5 (the United Kingdom, Germany, Spain, France, and Italy) and Japan) alone is expected to be 5,748,062 in 2020. The prevalent population is further expected to increase during the forecast period (2020–2030). For the study period 2017-2030, the Schizophrenia market is expected to increase with a CAGR of 6.89% in seven major markets.
Around 30% of the Schizophrenia patients are resistant to available antipsychotic drugs. Between 80-90% of the patients experience relapse due to nonadherence to maintenance therapy. This calls for an intensification of R&D in the Schizophrenia market space to better understand the MoA of the drugs, and offer quantitative biomarkers to predict the changing brain activity related to drug action.
To fulfill the need for the therapeutic agents potential enough to address cognitive impairment, and to overcome drug-resistance issues in the Schizophrenia market, some of the key companies such as Alkermes, Avineuro Pharma, Boehringer Ingelheim, GW Research, Karuna Pharma, Newron Pharma, Acadia Pharma, Minerva Neurosciences, BioXcel Therapeutics, Acadia Pharma, among several others are involved in the development of therapies for Schizophrenia.
For more detailed information on Schizophrenia Market, visit: https://www.delveinsight.com/blog/schizophrenia-market/